Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir Regimens in HCV Genotype 2
NCT02482077Phase 4Completed
- Sponsor
- Humanity & Health Research Centre
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sofosbuvir, daclatasvir and ledipasvir in hepatitis C (HCV) (6 arms), sponsored by Humanity & Health Research Centre. Primary endpoints: Sustained Virologic Response 12 weeks after discontinuation and Adverse events leading to permanent discontinuation of study drug(s). Started Jan 2015; status: completed.
02
Drugs
sofosbuvirdaclatasvirledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02482077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02482077.